Sector News

Novartis, Celgene meds take the biggest shares of cancer drug spending

May 28, 2015
Life sciences
Cancer drug spending is up. Cancer drug prices are way up. And as a new Express Scripts report shows, spending on each cancer patient is mounting; it’s among the reasons why a growing number of individual patients account for $100,000-plus in annual drug spending. And a few big drugs made big contributions to that rise.
 
As the American Society of Clinical Oncology meeting approaches, the pharmacy benefits manager released some numbers on cancer drug spending. The top line? Spending on cancer meds grew by more than one-fifth last year, with a 9% increase in use and almost 12% increase in prices.
 
Prime suspects for that increase? The leukemia treatment Gleevec, from Novartis, which boasts the biggest share of the market at 12.5%. Fellow blood cancer treatment Revlimid–the multiple myeloma therapy from Celgene–came in close behind with 10.8% of pharmacy benefit spending.
 
In third place by market share is Lupron Depot, the AbbVie med used to treat several conditions, including prostate cancer. And rounding out the top 5 were two newly generic chemotherapies, capecitabine, also sold by Roche under the brand name Xeloda; and temozolomide, the Merck & Co. pill Temodar that’s used to treat brain tumors.
 
And the growth shows no sign of slowing, the PBM said in a blog post, partly because of new meds coming to market–including Pfizer’s blockbuster-to-be breast cancer med Ibrance (palbociclib), Novartis’ myeloma med Farydak (panobinostat) and Eisai’s thyroid cancer treatment Lenvima (lenvatinib). Not to mention the PD-1/PD-L1 immunotherapies that are swiftly racking up data (and approvals) in multiple cancers, including Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo.
 
“Express Scripts expects cancer medications will maintain their lead position as a major contributor to drug spending in the pharmacy benefit, due to the availability of new medications and increased survival requiring long-term use of expensive and complex treatment,” the PBM notes.
 
That’s why Express Scripts is so keen on negotiating discounts with drugmakers, including pay-for-performance deals that would peg prices to results. It’s also why Express Scripts is impatiently waiting for–and lobbying on the behalf of–biosimilar meds. The PBM says 11 biosimilars closest to FDA approval could save the healthcare system $250 billion over the next decade. That would include Roche’s Avastin (bevacizumab) and Herceptin (trastuzumab), two of the top-selling cancer meds on the planet.
 
By Tracy Staton
 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach